DSpace Repository

Cost-benefit and cost-effectiveness of the incorporation of the pneumococcal 7-valent conjugated vaccine in the routine vaccination schedule of Catalonia (Spain)

Show simple item record

dc.contributor Universitat de Vic. Facultat d'Empresa i Comunicació
dc.contributor.author Navas, Elisa
dc.contributor.author Salleras, L.
dc.contributor.author Gisbert, Ramon
dc.contributor.author Dominguez, A.
dc.contributor.author Timoner, E.
dc.contributor.author Ibáñez Ibáñez, Diana
dc.contributor.author Prat, A.
dc.date.accessioned 2014-04-03T12:12:10Z
dc.date.available 2014-04-03T12:12:10Z
dc.date.created 2005
dc.date.issued 2005
dc.identifier.citation Navas, E., Salleras, L., Gisbert Gelonch, R., Domínguez, A., Timoner, E., Ibáñez, D., & Prat, A. (2005). Cost-benefit and cost-effectiveness of the incorporation of the pneumococcal 7-valent conjugated vaccine in the routine vaccination schedule of Catalonia (Spain).Vaccine, 23 (17-18), 2342-2348. ca_ES
dc.identifier.issn 0264-410X
dc.identifier.uri http://hdl.handle.net/10854/2845
dc.description.abstract The health and economic costs and benefits of vaccinating a cohort of 60,000 children born in Catalonia in the year 2000 with the pneumococcal 7-valent conjugated vaccine were compared with the alternative of not implementing the vaccination programme. The time horizon fixed for the programme was 10 years for invasive disease, 2 years for all episodes of pneumonia and otitis media and 3.5 years for the placement of tympanostomy tubes. In the base case (incidence rate of invasive disease of 160 per 100,000 and price of the vaccine 50 euros) the net present value was negative, both from the societal perspective (−5.1 million euros) and from the provider’s perspective (−9.2 million euros). The benefit-cost ratio was 0.59 euros from the societal perspective. The cost per disability adjusted life year (DALY) gained was 44,307 euros from the societal perspective and 80,291 euros from the provider’s perspective. ca_ES
dc.format application/pdf
dc.format.extent 7 p. ca_ES
dc.language.iso eng ca_ES
dc.publisher Elsevier ca_ES
dc.rights (c) 2005 Elsevier. Published article is available at: http://dx.doi.org/10.1016/j.vaccine.2005.01.018
dc.subject.other Vacunació -- Aspectes econòmics ca_ES
dc.subject.other Vacunació dels infants ca_ES
dc.subject.other Pneumònia en els infants ca_ES
dc.title Cost-benefit and cost-effectiveness of the incorporation of the pneumococcal 7-valent conjugated vaccine in the routine vaccination schedule of Catalonia (Spain) ca_ES
dc.type info:eu-repo/semantics/article ca_ES
dc.identifier.doi https://doi.org/10.1016/j.vaccine.2005.01.018
dc.relation.publisherversion http://www.sciencedirect.com/science/article/pii/S0264410X05000204
dc.rights.accessRights info:eu-repo/semantics/closedAccess ca_ES
dc.type.version info:eu-repo/publishedVersion ca_ES
dc.indexacio Indexat a SCOPUS ca_ES

Files in this item

Show simple item record

Search RIUVic


Advanced Search

Browse

Statistics